2012 Annual Report Lead Clinical Investigator Discovers  Eliquis  Benefits Close to Home When Dr. Christopher Granger’s mother was  diagnosed with atrial fibrillation five years ago at  the age of 79, she was prescribed warfarin, the  standard of care. Now, Granger, a cardiologist,  clinical researcher and professor of medicine at  Duke University, is switching her prescription to  Eliquis , Bristol-Myers Squibb’s newly approved  therapy to reduce the risk of stroke in patients  with nonvalvular atrial fibrillation. His decision for his mother is grounded on a  unique experience. Granger was the co-principal  investigator for  ARISTOTLE , the global Phase III  clinical trial that established the safety and effi - cacy profile of  Eliquis  versus warfarin, studying  more than 18,000 patients at 1,000 sites. “To study a promising new treatment for reducing  stroke in atrial fibrillation was a great opportunity,”  he says. “After all, we know that the strokes that  occur with fibrillation tend to be larger and more  disabling than other types of strokes. Reducing  risk of stroke is the dominant consideration when treating patients with atrial fibrillation.” Granger has participated in the  Eliquis  journey  for about seven years, beginning with the first  patients enrolled in  ARISTOTLE  in early 2006. “Those of us involved in clinical investigation are  constantly surprised and humbled by the results  of clinical trials. Sometimes we win and some- times we don’t. With this particular therapy, we  and the patients were very fortunate. The results  of  ARISTOTLE  – superiority for efficacy, a lower  rate of bleeding as well as a reduction in all- cause mortality – were stunning.” He sees the challenges ahead, especially in  getting some physicians to prescribe newer  agents like  Eliquis  instead of warfarin. “I call it  warfarin inertia,” he says. “There is a resistance to  change from something familiar, that you know  works well, to something new. But at the end of  the day, physicians must decide what is best for  the patient. That decision should be driven by  outcomes data.” 13 Bristol-Myers Squibb  Christopher B. Granger,M.D. 